Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_assertion type Assertion NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_head.
- NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_assertion description "[ This weekly irinotecan/docetaxel regimen has shown an acceptable toxicity profile while encouraging median and 1-year survival in heavily pretreated NSCLC patients. The tendency to better prognosis in patients carrying the variant genotypes 6/7 and 7/7 o]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_provenance.
- NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_assertion evidence source_evidence_literature NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_provenance.
- NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_assertion SIO_000772 14586211 NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_provenance.
- NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_assertion wasDerivedFrom gad-20150221 NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_provenance.
- NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_assertion wasGeneratedBy ECO_0000203 NP80650.RA0q7hRswg_IoO8l8qRQXkzDGY4XMMDvUcQTziSLvcHW8130_provenance.